Tag: Ltd.

BENGALURU, India, Aug. 01, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., एआई-संचालित औषधि खोज में अग्रणी संगठन, ने आज अपने RxAgentAI™ प्लेटफॉर्म में प्रमुख संवर्द्धन की घोषणा की, जिससे औषधि खोज की समय-सीमा आधी रह गई, साथ ही मेटाबोलिक और दुर्लभ रोगों से संबंधित अनेक उपचारों के सह-विकास के लिए AlphaMeld Corporation के साथ रणनीतिक सहयोग भी किया गया।

Company delivers record second quarter revenue, meets or exceeds all guidance metrics

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm’s length note payable by the issuance of 3,209,523 units, at a price of $0.021 per unit, being the same issue price and security being offering pursuant to the private placement.

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI^®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.